- DROXIDOPA
-
-
2026-03-13
- CAS:23651-95-8
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Droxidopa
-
- $73.00 / 5mg
-
2026-03-13
- CAS:23651-95-8
- Min. Order:
- Purity: 97.27%
- Supply Ability: 10g
- DROXIDOPA
-
- $1.00 / 1KG
-
2025-12-12
- CAS:23651-95-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200000KG
|
| | DROXIDOPA Basic information |
| Product Name: | DROXIDOPA | | Synonyms: | Droxidopa (JAN);L-threo-3,4-Dihydroxyphenylserine;L-threo-b-(3,4-Dihydroxyphenyl)serine;L-Tyrosine, b,3-dihydroxy-, threo-;L-Tyrosine, β,3-dihydroxy-, (βR)-;Serine, 3-(3,4-dihydroxyphenyl)-, L-threo- (8CI);SM 5688;threo-Dopaserine | | CAS: | 23651-95-8 | | MF: | C9H11NO5 | | MW: | 213.19 | | EINECS: | | | Product Categories: | Amines;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors | | Mol File: | 23651-95-8.mol |  |
| | DROXIDOPA Chemical Properties |
| Melting point | 232-235° (dec); mp 229-232° (dec) (Ohashi) | | alpha | D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl) | | Boiling point | 549.8±50.0 °C(Predicted) | | density | 1.608±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: ≥3mg/mL | | pka | 2.09±0.24(Predicted) | | form | powder | | color | white to tan | | Merck | 14,3457 | | Stability: | Hygroscopic | | InChI | InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/s3 | | InChIKey | QXWYKJLNLSIPIN-WWXSATIUNA-N | | SMILES | [C@H](C1C=CC(O)=C(O)C=1)(O)[C@H](N)C(=O)O |&1:0,10,r| | | CAS DataBase Reference | 23651-95-8 |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | RTECS | VT9626010 | | HS Code | 29225090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | DROXIDOPA Usage And Synthesis |
| Description | Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed
from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa
added to existing levodopa/decarboxylase inhibitor therapy produces significant
improvements in retropulsion, dysarthria and muscular rigidity refractory to other
treatments; however, tremor was unaffected. | | Description | Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 μg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa , indicating that the mechanism is peripheral. Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension. | | Chemical Properties | Off-White Solid | | Originator | Sumitomo (Japan) | | Uses | The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian. | | Uses | Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). | | Uses | L-DOPS has been administered for clinical trial studies in mice with amyloid pathology. | | Definition | ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension | | Brand name | DOPS | | General Description | L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology. | | Biochem/physiol Actions | L-DOPS is a norepinephrine precursor in vivo. | | References | [1] J BARTHOLINI. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.[J]. Journal of Pharmacology and Experimental Therapeutics, 1975, 193 2: 523-532.
[2] MAR COLL. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats[J]. Hepatology, 2012, 56 5: 1849-1860. DOI: 10.1002/hep.25845
[3] HORACIO KAUFMANN Jose A P Lucy Norcliffe Kaufmann. Droxidopa in neurogenic orthostatic hypotension.[J]. Expert Review of Cardiovascular Therapy, 2015, 13 8: 875-891. DOI: 10.1586/14779072.2015.1057504 |
| | DROXIDOPA Preparation Products And Raw materials |
|